Regeneron Pharma falls after quarterly results miss
Drugmaker Regeneron Pharmaceuticals' REGN.O shares fall 7% to $568 premarket
Co posts Q1 adj. profit of $8.22/shr, missing analysts' estimates of $8.82, according to data compiled by LSEG
Reports Q1 revenues of $3.03 billion vs estimates of $3.27 billion
Says global sales for its blockbuster lung disease drug, Dupixent, rose 19% in Q1 to $3.67 billion
However, U.S. sales of dry eye disease drugs Eylea and Eylea HD fell 26% to $1.4 billion
"While we anticipated this may be a more messy quarter for Eylea due to ongoing funding concerns for patient assistance charities, other factors further exacerbated this dynamic" - Brokerage BMO Capital Markets
As of last close, REGN has fallen 14.2% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Micron Stock Forecast: Can the AI Memory Super-Cycle Drive MU to $3,000 by 2030?

Tesla Opens Up Over 2%, Shares Return to $400, Here Is What Investors Need to Note

Gold Price Forecast: U.S.-Iran Tensions Ease, Nonfarm Payrolls Looming, What’s Next for Gold?

SpaceX IPO Approaches: Musk Dissolves xAI into SpaceX and Subleases 300MW Compute to Anthropic; Can the $2 Trillion Valuation Hold?

WTI and Brent Futures Both Fall Below $100 Mark, Have Oil Prices and Energy Sector Peaked?

Tradingkey








